AFF3 upregulation mediates tamoxifen resistance in breast cancers

BACKGROUND: Although tamoxifen is a highly effective drug for treating estrogen receptor–positive (ER(+)) breast cancer, nearly all patients with metastasis with initially responsive tumors eventually relapse, and die from acquired drug resistance. Unfortunately, few molecular mediators of tamoxifen...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Yawei, Zhao, Yang, Zhang, Yunjian, AiErken, NiJiati, Shao, Nan, Ye, Runyi, Lin, Ying, Wang, Shenming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192118/
https://www.ncbi.nlm.nih.gov/pubmed/30326937
http://dx.doi.org/10.1186/s13046-018-0928-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192118/
https://www.ncbi.nlm.nih.gov/pubmed/30326937
http://dx.doi.org/10.1186/s13046-018-0928-7

Ejemplares similares